Michael Safdi
Overview
Explore the profile of Michael Safdi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lichtenstein G, Feagan B, Mahadevan U, Salzberg B, Langholff W, Morgan J, et al.
Am J Gastroenterol
. 2018 Jul;
113(11):1678-1688.
PMID: 30022113
Objectives: We described pregnancy outcomes in Crohn's disease (CD) patients enrolled in the TREAT Registry who received infliximab before, or during pregnancy and those not treated with infliximab or any...
2.
Lichtenstein G, Feagan B, Cohen R, Salzberg B, Safdi M, Popp Jr J, et al.
Inflamm Bowel Dis
. 2018 Feb;
24(3):490-501.
PMID: 29462395
Background: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn's disease (CD) therapy. Methods: Patients with CD were prospectively evaluated in...
3.
Berry S, Barish C, Bhandari R, Clark G, Collins G, Howell J, et al.
BMC Gastroenterol
. 2013 Jul;
13:106.
PMID: 23815124
Background: Complications of chronic anal fissure (CAF) treatments are prompting interest in lower-risk therapies. This study was conducted to compare nitroglycerin (NTG) 0.4% ointment with placebo for pain associated with...
4.
Sninsky C, Safdi M, Katz S
Gastroenterol Hepatol (N Y)
. 2011 Sep;
4(2 Suppl 4):1-12.
PMID: 21904481
No abstract available.
5.
Kane S, Katz S, Jamal M, Safdi M, Dolin B, Solomon D, et al.
Inflamm Bowel Dis
. 2011 Aug;
18(6):1026-33.
PMID: 21837775
Background: This was a phase IV, multicenter, open-label, 12-14-month study to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX)...
6.
Sandborn W, Korzenik J, Lashner B, Leighton J, Mahadevan U, Marion J, et al.
Gastroenterology
. 2010 Jan;
138(4):1286-96, 1296.e1-3.
PMID: 20064514
Background & Aims: The practice of dosing mesalamines in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity. This convention and...
7.
Safdi M, Bekal P, Martin S, Saeed Z, Burton F, Toskes P
Pancreas
. 2006 Jul;
33(2):156-62.
PMID: 16868481
Objectives: Creon 10 Minimicrospheres is an enteric-coated, delayed-release pancrelipase preparation designed to deliver active pancreatic enzymes to the small intestine. The primary objective of this study was to compare the...
8.
Sands B, Sandborn W, Wolf D, Katz S, Safdi M, Schwartz D, et al.
J Clin Gastroenterol
. 2006 Jul;
40(6):482-9.
PMID: 16825929
Goals: Two uncontrolled, multicenter feasibility studies evaluated safety and pilot efficacy of selective granulocyte and monocyte adsorption apheresis (GMA) with the Adacolumn Apheresis System for treatment of moderate-to-severe ulcerative colitis...
9.
Rutgeerts P, Diamond R, Bala M, Olson A, Lichtenstein G, Bao W, et al.
Gastrointest Endosc
. 2006 Feb;
63(3):433-42.
PMID: 16500392
Background: The endoscopic substudy of the ACCENT I (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen) Crohn's disease trial examined the effects of infliximab on...
10.
Hanauer S, Sandborn W, Kornbluth A, Katz S, Safdi M, Woogen S, et al.
Am J Gastroenterol
. 2005 Nov;
100(11):2478-85.
PMID: 16279903
Background And Aims: Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to...